Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/2/2011

181, a novel mu-opioid analgesic molecule wholly-owned by Nektar, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel proprietary topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development stage products that leverage Nektar's proprietary technology platform include peginesatide, for which Affymax and partner Takeda submitted an NDA to the FDA in May 2011, and Baxter's BAX 855, a long-acting PEGylated rFVIII program planned to enter Phase 1 clinical development in 2011.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements including but not limited to Nektar's plans to initiate the Phase 3 BEACON study for NKTR-102 in metastatic breast cancer before year-end, plans to complete a Phase 1 clinical study for NKTR-181 and announce those results before year end, AstraZeneca's plans for regulatory filings in 2013, Baxter's plans to advance BAX 855 into Phase 1 clinical development prior to year end, Nektar's plan to file an investigational new drug application for NKTR-192 in the first quarter of 2012, and the value and potential of Nektar's R&D pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaborati
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... --   Masimo (NASDAQ: MASI ... Acoustic Monitoring™, and Masimo SET ® Measure-Through Motion ... Medical Devices, Inc. dismissed all outstanding claims against Masimo ... and Cercacor.   Masimo did not incur any liability to ...
... QBC Diagnostics, a global manufacturer of hematology ... the company has been awarded a U.S. General ... Equipment and Services. GSA,s Scientific Equipment ... with scientific instruments for a wide variety of ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4QBC Diagnostics Awarded GSA Contract 2
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... submit abstracts to present their research at the ... to molecular imaging and nuclear medicineJune 13-17, 2009, ... molecular imaging is vital and state-of-the-art," said SNM ... society,s more than 17,000 molecular imaging and nuclear ...
... associated with an increased risk of fetal growth restriction ... bmj.com today. , Although some previous studies ... that any amount and type of caffeine intakefrom tea, ... as coffeeis linked with relatively slower fetal growth. ...
... Nov. 3 Pregis Corporation, a leading,international ... and specialty packaging solutions, will conduct an ... quarter results on Friday,November 14, 2008 at ... 800-591-6942;,International: 617-614-4909; Participant Passcode: 68623125. A replay ...
... QIAGEN N.V.,(Nasdaq: QGEN ) today announced the Webcast of ... at 9:30 a.m. EST on,Tuesday, November 11, and will include remarks ... Chief Financial Officer., What: Webcast ... 9:30 a.m. EST on November 11, Where: ...
... common correction techniques yield positive results, ROSEMONT, ... used to correct the condition known as clubfoot,have ... new study published,in the November 2008 issue of ... ). While both treatment strategies use different,approaches, each ...
... ANGELES, Nov. 3 World Champion athlete and ... debut as a member of the,California Governor,s Council ... speaking to the student body of NEW Academy ... and healthy lifestyles., (Photo: http://www.newscom.com/cgi-bin/prnh/20081103/AQM074 ), ...
Cached Medicine News:Health News:SNM to showcase the latest research in molecular imaging and nuclear medicine 2Health News:Consuming small amounts of caffeine when pregnant may affect the growth of an unborn child 2Health News:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11 2Health News:Non-Surgical Clubfoot Treatments Bring High Level of Success 2Health News:Non-Surgical Clubfoot Treatments Bring High Level of Success 3Health News:Laila Ali Debuts as Member of California Governor's Council on Physical Fitness and Sports 2
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues to ... sample processing, now with 1,048,000 x g ... rotor. DiscoveryTMM150SE processes sample sizes from ... small floor footprint, brushless direct drive, very ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Optima L-XP ultracentrifuge is designed to ... discovery process if research involves proteomics, ... sophisticated on-board computer, enhanced firmware, powerful ... touch screen, Optima L-XP delivers superior ...
... chemistry system brings versatility in a ... laboratory. A model of innovation and ... system features state-of-the-art Dimension testing technology, ... in a flexible. affordable, easy-to-use system ...
Medicine Products: